AstraZeneca profits drop

AstraZeneca Profit Dives 56% in Q3

Oct. 25, 2012
Revenue loss from expiration of patents on popular drugs

As group revenues tumbled on the expiry of key drug patents, pharmaceuticals giant AstraZeneca (IW 1000/131) on Thursday said its net profits sank 56% in the third quarter.

Earnings after tax slumped to $1.53 billion in the three months to the end of September, compared with $3.48 billion in the same period of 2011.

Sales tumbled 19% to $6.68 billion.

"As expected, the revenue decline in the third quarter reflected the ongoing effect from the loss of exclusivity on several brands," AstraZeneca said in the statement.

The company added that its financial targets for the full year remained unchanged.

The company is facing crucial patent expires up until 2015 on drugs such as schizophrenia treatment Seroquel and heartburn and ulcer drug Nexium.

It will also suffer the loss of patent protection in the United States for its best-selling anti-cholesterol drug, Crestor, in 2016.

The latest earnings update was meanwhile the first under the group's new chief executive Pascal Soriot. The Frenchman who was previously a senior executive at Swiss drugs group Roche took up his role at the start of October following the resignation of American David Brennan, who stepped down as AstraZeneca boss in April.

"As I take up my new role as chief executive, my priority is to restore the company to growth and scientific leadership," Soriot said.

Earlier this year, Brennan announced plans to cut 7,300 jobs by 2014 to improve profitability at AstraZeneca, which has come under heavy pressure in recent times from generic drugs competition.

Copyright Agence France-Presse, 2012

About the Author

Agence France-Presse

Copyright Agence France-Presse, 2002-2017. AFP text, photos, graphics and logos shall not be reproduced, published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP shall not be held liable for any delays, inaccuracies, errors or omissions in any AFP content, or for any actions taken in consequence.

Sponsored Recommendations

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!